- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00382447
Breath Actuated Nebulizer Study Protocol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Generic nebulizers as well as breath actuated nebulizers have been available and FDA approved to administer therapy for years. Recently there has been interest in using breath actuated nebulizers to stream-line patient care in the hospital setting. Literature has found that breath actuated nebulizers are not only faster at delivering an equivalent dose, but more effective when measuring patient response to that therapy. There is no standard for method of converting from generic nebulizers to breath actuated technology.
Objectives:
We want to evaluate the use of Breath Actuated Nebulizer (BAN) technology versus generic nebulizers to improve quality of patient treatments and reduce nebulization duration to allow staff time to do complete patient assessments.
Inclusion Criteria:
- Adult patients with orders for routine 2.5 mg albuterol sulfate nebulizer therapy ordered either Q4 or Q6 hours who consent to the study.
Exclusion Criteria:
- Adults with nebulizer therapy ordered more frequently than Q4 hours.
- Adults with nebulizer therapy ordered less frequently than Q6 hours.
- Pregnant patients are excluded.
- Adults with orders for albuterol sulfate > 2.5 mg.
- Adults in the intensive care unit (ICU) or Emergency Department.
Protocol:
- Adult patient ordered for Q4 to Q6 2.5 mg albuterol sulfate nebulizer therapy with or without anticholinergic agent (ipratropium/tiotropium)
- Patient is consented
- Patient is randomized to receive either "Control Method" or "Study Method" first (see methods below)
- The 1st morning after consent, the first study method is used
- The 2nd morning after consent, the other study method is used
- Study is over after the second study method is completed
Control Method:
Baseline patient data with spirometry is recorded including:
Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1),Forced Expiratory Ratio (FER), Peak Expiratory Flow (PEF), HR, Resting RR, Breath sounds, Pulse Oximetry (SpO2).
- 2.5 mg albuterol sulfate is given with generic nebulizer for the 0700 treatment time. Anticholinergic agents such as ipratropium or tiotropium are given as ordered.
- Follow-up patient data with spirometry is recorded at 15 minutes and 2 hours following the treatment.
- Subsequent treatments that day are given as standard.
Study Method:
Baseline patient data with spirometry is recorded including:
Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1),Forced Expiratory Ratio (FER), Peak Expiratory Flow (PEF), Heart rate (HR), Resting respiratory rate (RR), Breath sounds, Pulse Oximetry (SpO2).
- Albuterol sulfate (2.5 mg) is given via Aero Eclipse BAN with 0.5 ml of saline or 0.5 ml of ipratropium bromide (if ipratropium bromide is ordered).
- Follow-up patient data with spirometry is recorded at 15 minutes and 2 hours following the treatment.
- Subsequent treatments that day are given as ordered.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19718
- Christiana Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients with orders for routine 2.5 mg albuterol sulfate nebulizer therapy ordered either Q4 or Q6 hours who consent to the study.
Exclusion Criteria:
- Adults with nebulizer therapy ordered more frequently than Q4 hours.
- Adults with nebulizer therapy ordered less frequently than Q6 hours.
- Pregnant patients are excluded.
- Adults with orders for albuterol sulfate > 2.5 mg.
- Adults in the ICU or Emergency Department.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Standard nebulizer versus standard breath actuated nebulizer
|
Standard small volume nebulizer for aerosolized medication delivery
Nebulizer that dispenses medication only during the inspiratory phase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Forced vital capacity
Time Frame: 1
|
1
|
FEV1
Time Frame: 1
|
1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John S. Emberger, BS, Christiana Care Health Services
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCC# 26168
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on standard nebulizer
-
Centre Hospitalier Universitaire de NīmesCompleted
-
National Institute of Nursing Research (NINR)Completed
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Medstar Health Research InstituteWithdrawnChronic Obstructive Pulmonary DiseaseUnited States
-
Cliniques universitaires Saint-Luc- Université...Fonds National de la Recherche ScientifiqueUnknownAerosol Drug TherapyBelgium
-
Guangzhou Institute of Respiratory DiseaseCompletedCovid-19 | Dyspnea | Hydrogen/Oxygen Mixed GasChina
-
Hamilton Health Sciences CorporationCompleted
-
Tufts Medical CenterCompleted
-
Eda SORKUNCompleted